The use of in vivo dosimetry within the combined
treatment of uterine corpus cancer

Relevance: Radiotherapy is the standard post-surgery treatment in patients with uterine corpus cancer. However, radiotherapy affects 90.0–100.0% of the volume of risk organs. Information on the actual dose delivered to critical structures is needed to ensure the quality of radiotherapy. The purpose of this study was to determine the impact of the type of ionizing radiation on the dose load on the rectal mucosa using in vivo dosimetry. Results: At the first and tenth sessions of treatment using a cobalt apparatus, the in vivo dosimetry showed that the minimum value of the dose received during the tenth cycle was higher by 0.1 Gy. That is, the deviations from the planned dose were less at the same maximum values. Both the average value and the median during the tenth cycle were also moderately higher. The relative difference between the dose planned and received during the tenth cycle was higher than during the first cycle by an average of 1.12575%, with a median of 0.82214. When conducting radiotherapy using a linear accelerator, the average and median values were higher in the second measurement despite almost identical minimum and maximum values. The relative difference between the planned and received doses during the tenth cycle was higher than during the first cycle by an average of 0.55619%, with a median of 0.42948. Conclusion: The conducted study showed an intro- and interindividual variability of in vivo dosimetry results during radiotherapy of genital cancer patients. In vivo dosimetric control showed that the relative difference between the doses calculated and received by the rectal mucosa upon reaching of 20.0 Gy dose in comparison to the first irradiation cycle was twice higher on the ROCUS-AM cobalt apparatus vs. the Clinac 600 C linear accelerator. The data obtained during the investigation indicates the need to develop innovative approaches to topometric preparation of genital cancer patients and to continue their dosimetric monitoring to establish the causes of discrepancies in the results.

Download Full-text

The use of in vivo dosimetry within the combined treatment of uterine body cancer

Oncologia i radiologia Kazakhstana ◽

10.52532/2521-6414-2020-1-55-35-38 ◽

2020 ◽

Vol 55 (1) ◽

pp. 35-38

Author(s):

O. M. Sukhina ◽

V. S. Sukhin ◽

Y. B. Radzishevska ◽

A. S. Sіmbіrova

Keyword(s):

Cancer Patients ◽

Linear Accelerator ◽

Uterine Cancer ◽

Combined Treatment ◽

Relative Difference ◽

In Vivo Dosimetry ◽

Genital Cancer ◽

Post Surgery ◽

The Impact

Relevance: Radiotherapy is the standard post-surgery treatment in patients with uterine cancer. However, radiotherapy affects 90.0–100.0% of the volume of risk organs. Information on the actual dose delivered to critical structures is needed to ensure the quality of radiotherapy. The purpose of this study was to determine the impact of the type of ionizing radiation on the dose load on the rectal mucosa using in vivo dosimetry. Results: At the first and tenth sessions of treatment using a cobalt apparatus, the in vivo dosimetry showed that the minimum value of the dose received during the tenth cycle was higher by 0.1 Gy. That is, the deviations from the planned dose were less at the same maximum values. Both the average value and the median during the tenth cycle were also moderately higher. The relative difference between the dose planned and received during the tenth cycle was higher than during the first cycle by an average of 1.12575%, with a median of 0.82214. When conducting radiotherapy using a linear accelerator, the average and median values were higher in the second measurement despite almost identical minimum and maximum values. The relative difference between the planned and received doses during the tenth cycle was higher than during the first cycle by an average of 0.55619%, with a median of 0.42948. Conclusion: The conducted study showed an intro- and interindividual variability of in vivo dosimetry results during radiotherapy of genital cancer patients. In vivo dosimetric control showed that the relative difference between the doses calculated and received by the rectal mucosa upon reaching of 20.0 Gy dose in comparison to the first irradiation cycle were twice higher on the ROCUS-AM cobalt apparatus vs. the Clinac 600 C linear accelerator. The data obtained during the investigation indicates the need to develop innovative approaches to topometric preparation of genital cancer patients and to continue their dosimetric monitoring to establish the causes of discrepancies in the results.

Download Full-text

In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy

International Journal of Molecular Sciences ◽

10.3390/ijms22189762 ◽

2021 ◽

Vol 22 (18) ◽

pp. 9762

Author(s):

Junko Takahashi ◽

Shinsuke Nagasawa ◽

Motomichi Doi ◽

Masamichi Takahashi ◽

Yoshitaka Narita ◽

...

Keyword(s):

Ionizing Radiation ◽

Aminolevulinic Acid ◽

Combined Treatment ◽

Reactive Oxygen Species Generation ◽

Photodynamic Diagnosis ◽

High Dose ◽

Severe Toxicity ◽

Fractionated Radiotherapy ◽

Post Surgery

To treat malignant glioma, standard fractionated radiotherapy (RT; 60 Gy/30 fractions over 6 weeks) was performed post-surgery in combination with temozolomide to improve overall survival. Malignant glioblastoma recurrence rate is extremely high, and most recurrent tumors originate from the excision cavity in the high-dose irradiation region. In our previous study, protoporphyrin IX physicochemically enhanced reactive oxygen species generation by ionizing radiation and combined treatment with 5-aminolevulinic acid (5-ALA) and ionizing radiation, while radiodynamic therapy (RDT) improved tumor growth suppression in vivo in a melanoma mouse model. We examined the effect of 5-ALA RDT on the standard fractionated RT protocol using U251MG- or U87MG-bearing mice. 5-ALA was orally administered at 60 or 120 mg/kg, 4 h prior to irradiation. In both models, combined treatment with 5-ALA slowed tumor progression and promoted regression compared to treatment with ionizing radiation alone. The standard fractionated RT protocol of 60 Gy in 30 fractions with oral administration of 120 and 240 mg/kg 5-ALA, the human equivalent dose of photodynamic diagnosis, revealed no significant increase in toxicity to normal skin or brain tissue compared to ionizing radiation alone. Thus, RDT is expected to enhance RT treatment of glioblastoma without severe toxicity under clinically feasible conditions.

Download Full-text

PO-0962: Correlation between DVHs and in-vivo dosimetry measurements in OARs for brachytherapy cervix cancer patients

Radiotherapy and Oncology ◽

10.1016/s0167-8140(15)33268-0 ◽

2013 ◽

Vol 106 ◽

pp. S371

Author(s):

T.S. Gudmundsdóttir ◽

G. Myrdal ◽

M.V. Sastre Padro

Keyword(s):

Cancer Patients ◽

Cervix Cancer ◽

In Vivo Dosimetry

Download Full-text

SU-GG-T-05: MOSFET In-Vivo Dosimetry for Colorectal Cancer Patients Treated with Shielded Brachytherapy

Medical Physics ◽

10.1118/1.2961755 ◽

2008 ◽

Vol 35 (6Part8) ◽

pp. 2727-2727

Author(s):

C Furstoss ◽

X Yan ◽

B Reniers ◽

E Poon ◽

A Hallil ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

In Vivo Dosimetry ◽

Colorectal Cancer Patients

Download Full-text

In vivo dosimetry of high-dose-rate brachytherapy: Study on 61 head-and-neck cancer patients using radiophotoluminescence glass dosimeter

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2004.10.031 ◽

2005 ◽

Vol 61 (3) ◽

pp. 945-953 ◽

Cited By ~ 17

Author(s):

Takayuki Nose ◽

Masahiko Koizumi ◽

Ken Yoshida ◽

Kinji Nishiyama ◽

Junichi Sasaki ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Dose Rate ◽

Cancer Patients ◽

Neck Cancer ◽

High Dose Rate ◽

In Vivo Dosimetry ◽

High Dose ◽

Glass Dosimeter

Download Full-text

A combined treatment approach for cachexia and cancer-related anemia in advanced cancer patients: A randomized placebo-controlled trial.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.31_suppl.189 ◽

2014 ◽

Vol 32 (31_suppl) ◽

pp. 189-189 ◽

Cited By ~ 2

Author(s):

Clelia Madeddu ◽

Giulia Gramignano ◽

Luciana Tanca ◽

Maria Cristina Cherchi ◽

Carlo Aurelio Floris ◽

...

Keyword(s):

Energy Metabolism ◽

Cancer Patients ◽

Advanced Cancer ◽

Cancer Progression ◽

Iron Metabolism ◽

Combined Treatment ◽

Advanced Cancer Patients ◽

Tnf Α ◽

Cancer Related Anemia ◽

The Impact

189 Background: Cancer progression is characterized by specific energy metabolism alterations and by symptoms including fatigue, anorexia, nausea, depression, which results in cachexia syndrome and compromised quality of life (QL). This condition is often associated to anemia (cancer-related anemia, CRA), which negatively impacts patient QL and disease outcome. Methods: Adult advanced cancer patients with cachexia (i.e., weight loss > 5% in the previous 6 months) and CRA were randomly assigned (1:1 by computer generated list) to receive 3 months of a combined approach consisting of celecoxib (200 mg/day), L-carnitine (2 g/day), curcumin (Meriva) (4 g/day) and lactoferrin (200 mg/day) or placebo. The rationale for selecting these agents was: L-carnitine for modulating cell energy metabolism; celecoxib for counteracting inflammation, which is a key feature of cachexia; curcumin for its antiinflammatory and antioxidant action, without disregarding its action on the NF-kB and JAK-STAT pathway and the related synthesis of proinflammatory cytokines; lactoferrin for its ability to regulate iron metabolism in anemic cancer patients. Primary endpoints were improvement of lean body mass (LBM), appetite, fatigue and anemia. Additionally, we assessed the impact of treatment on the main metabolic/inflammatory and iron metabolism parameters: C-reactive protein (CRP), interleukin (IL)-6, tumor necrosis factor (TNF)-α, leptin, reactive oxygen species (ROS), glutathione peroxidase, serum iron, ferritin, hepcidin and erythropoietin (EPO). Results: From January 2013 to March 2014, 66 patients have been enrolled. The combination arm was more effective than placebo arm in improving body weight, LBM, appetite, fatigue, and anemia. Among secondary parameters IL-6, TNF-α, CRP, ROS, ferritin, hepcidin and EPO decreased, while leptin increased significantly in the combination arm. No significant changes were observed in the placebo arm. Conclusions: To date a standard effective treatment of cancer cachexia is lacking. Our combined multitargeted approach was able to improve the nutritional and immunometabolic alterations of cachexia, ameliorate patient QL and correct CRA.

Download Full-text